Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27914480 | 1.00 | KIF11 (0.46) | KIF11HRH1HTR2ASLC7A5MAOA | |
| SCHEMBL2390381 | 0.92 | HRH1 (0.50) | KIF11HRH1HTR2AMAOA | |
| Acetic Acid SCHEMBL30066547 | 0.91 | CPB2 (0.41) | KIF11CPB2DPP8DPP9DPP7 | |
| SCHEMBL1040140 | 0.87 | KIF11 (0.57) | KIF11SLC7A5 | |
| SCHEMBL3475085 | 0.87 | KIF11 (0.57) | KIF11SLC7A5 | |
| SCHEMBL569409 | 0.84 | HRH1 (0.46) | KIF11HRH1HTR2A | |
| SCHEMBL28089585 | 0.84 | KDM4E (0.39) | KIF11 | |
| SCHEMBL7993168 | 0.81 | CSNK1E (0.45) | KIF11HTR2A | |
| SCHEMBL7761544 | 0.81 | KIF11 (0.46) | KIF11HRH1HTR2ASLC7A5MAOA | |
| SCHEMBL29788858 | 0.79 | KIF11 (0.41) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975232-B2 | Macrocyclic kinase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130178429-A1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120244079-A1 | TRACEABLE RETINOID ACID FOR IMAGING, DISEASE PREVENTION AND THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012016186-A1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011011105-A2 | TRACEABLE RETINOID ACID FOR IMAGING, DISEASE PREVENTION AND THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2011-01-27 | — | — | WO | disclosed |
| EP-1996217-B1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTPR LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-20100041613-A1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2010-02-18 | — | — | US | disclosed |
| EP-1996217-A4 | NOVEL ANTIBIOTIC COMPOSITIONS | INFLAZYME PHARM LTD (CA) | 2009-08-12 | — | — | EP | disclosed |
| EP-1691845-A4 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1996217-A2 | NOVEL ANTIBIOTIC COMPOSITIONS | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007103548-A2 | NOVEL ANTIBIOTIC COMPOSITIONS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-13 | — | — | WO | disclosed |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1691845-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | Bristol-Myers Squibb Pharma Company (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1644023-A2 | MELANOCORTIN RECPTOR 4(MC4) AGONISTS AND THEIR USES | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023314-A1 | COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005000339-A2 | MELANOCORTIN RECEPTOR 4(MC4) AGONISTS AND THEIR USES | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-1999004895-A1 | COMPOSITIONS FOR THE STORAGE AND DELIVERY OF SOLID PHASE REACTIVE PARTICLES AND METHODS OF USING THE SAME | ARGONAUT TECHNOLOGIES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | MC4R, MC3R, MC1R | KIF11 3801/4885HRH1 1313/4885HTR2A 222/4885 |
| US-20100041613-A1 | NOVEL ANTIBIOTIC COMPOSITIONS | MRPL21, NRDC, OTUB1 | KIF11 1315/4885HRH1 3311/4885HTR2A 4800/4885 |
| US-20130178429-A1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | MAP3K20, MAP3K11, MAP3K1 | KIF11 1094/4885HRH1 669/4885HTR2A 3378/4885 |
| US-20120244079-A1 | TRACEABLE RETINOID ACID FOR IMAGING, DISEASE PREVENTION AND THERAPY | STRA6, RARA, RXRA | KIF11 2826/4885HRH1 3179/4885HTR2A 4061/4885 |
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | KIF11 3735/4885HRH1 2754/4885HTR2A 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.